Emplagliflozin: New Indication
Until recently JardianceÒ (empagliflozin) by Beringer Ingelheim is used by diabetologists only for treatment of type 2 diabetes.
However, as evidenced by clinical studies, it turned out to be effective against cardiovascular disorders (CVD), which is a risk for patients with type 2 diabetes.
The conclusion on cardiovascular safety of the drug was based on the data obtained in a large-scale study EMPA-REG OUTCOME®, comparing the active drug against placebo in addition to the standard treatment with hypoglycaemic and cardiovascular disorders in type 2 diabetes patients with confirmed cardiovascular conditions.
The effectiveness of the drug was officially supported by the US Food and Drug Administration (FDA). The new indication has been approved by the Ministry of healthcare of the Russian Federation as well.